Tumors after kidney transplantation: a population study.

Autor: Ietto G; General, Emergency and Transplant Surgery Department, ASST-Sette Laghi and University of Insubria, Varese, Italy. giuseppe.ietto@gmail.com., Gritti M; Department of General Surgery, Humanitas Clinical and Research Center, Milan, Italy., Pettinato G; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA., Carcano G; General, Emergency and Transplant Surgery Department, ASST-Sette Laghi and University of Insubria, Varese, Italy., Gasperina DD; Department of Medicine and Surgery, University of Insubria, Varese, Italy.
Jazyk: angličtina
Zdroj: World journal of surgical oncology [World J Surg Oncol] 2023 Jan 23; Vol. 21 (1), pp. 18. Date of Electronic Publication: 2023 Jan 23.
DOI: 10.1186/s12957-023-02892-3
Abstrakt: One of the main causes of post-transplant-associated morbidity and mortality is cancer. The aims of the project were to study the neoplastic risk within the kidney transplant population and identify the determinants of this risk. A cohort of 462 renal transplant patients from 2010 to 2020 was considered. The expected incidence rates of post-transplant cancer development in the referenced population, the standardized incidence ratios (SIR) taking the Italian population as a comparison, and the absolute risk and the attributable fraction were extrapolated from these cohorts of patients. Kidney transplant recipients had an overall cancer risk of approximately three times that of the local population (SIR 2.8). A significantly increased number of cases were observed for Kaposi's sarcoma (KS) (SIR 195) and hematological cancers (SIR 6.8). In the first 3 years post-transplant, the risk to develop either KS or hematological cancers was four times higher than in the following years; in all cases of KS, the diagnosis was within 2 years from the transplant. Post-transplant immunosuppression represents the cause of 99% of cases of KS and 85% of cases of lymphomas, while only 39% is represented by solid tumors. Data related to the incidence, the percentages attributable to post-transplant immunosuppression, and the time of onset of neoplasms, particularly for KS and hematological tumors could help improve the management for the follow-up in these patients.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje